Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A

PURPOSE: Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of beroctocog alfa in patients of ages ≥12 years previously treated for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Shin Young, Park, Seon Yang, Lee, Soon Yong, Kook, Hoon, Paik, Sang Hoon, Jang, In-Jin, Lee, Kun Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479860/
https://www.ncbi.nlm.nih.gov/pubmed/26069114
http://dx.doi.org/10.3349/ymj.2015.56.4.935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479860/
https://www.ncbi.nlm.nih.gov/pubmed/26069114
http://dx.doi.org/10.3349/ymj.2015.56.4.935

Ejemplares similares